WEIGAO GROUP (01066) has announced the 2025 preliminary results of its subsidiary, Shandong Weigao Orthopaedic Device Co., Ltd. (688161). The company achieved operating revenue of RMB 1.539 billion, representing a year-on-year increase of 5.95%. Net profit attributable to the parent company's shareholders was RMB 267 million, up 19.17% compared to the previous year. Basic earnings per share stood at RMB 0.67.
During the reporting period, the volume-based procurement policy for orthopaedic products was implemented steadily, with leading domestic brands continuing to gain market share. On the sales front, the company proactively adjusted its sales model and organizational structure, establishing a profit center system centered around specialized clinical departments to drive optimization and upgrade of the marketing framework, thereby invigorating the sales organization.
By further segmenting product lines and implementing refined management through specialized sales divisions, the company enhanced the professional capabilities and focus of its sales team, enabling more precise clinical services and academic leadership in the market. Through coordinated multi-product line sales focused on key surgical procedures, significant business growth was achieved in core hospitals. Additionally, efforts to develop lower-tier markets and promote innovative products contributed to a sustained increase in overall surgical volumes, leading to continuous growth in both revenue and sales volume.
Comments